ALNYLAM PHARMACEUTICALS, INC. Interest Expense Nonoperating
ALNYLAM PHARMACEUTICALS, INC. (ALNY) reported Interest Expense Nonoperating of $82.05 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Expense Statement
us-gaap:InterestExpenseNonoperating · last filed 2026-07-30
- ALNYLAM PHARMACEUTICALS, INC. interest expense nonoperating for the quarter ending 2026-06-30 was $82.05M, a 33.51% increase year-over-year.
- ALNYLAM PHARMACEUTICALS, INC. interest expense nonoperating for the quarter ending 2025-12-31 was $65.40M, a 67.82% increase year-over-year.
- ALNYLAM PHARMACEUTICALS, INC. interest expense nonoperating for the quarter ending 2025-09-30 was $44.40M, a 29.15% increase year-over-year.
- ALNYLAM PHARMACEUTICALS, INC. interest expense nonoperating for the quarter ending 2025-06-30 was $61.46M, a 84.79% increase year-over-year.
- ALNYLAM PHARMACEUTICALS, INC. interest expense nonoperating for fiscal 2025 was $252.63M, a 78.08% increase from fiscal 2024.
- ALNYLAM PHARMACEUTICALS, INC. interest expense nonoperating for fiscal 2024 was $141.86M, a 17.02% increase from fiscal 2023.
- ALNYLAM PHARMACEUTICALS, INC. interest expense nonoperating for fiscal 2023 was $121.22M, a 22.28% decline from fiscal 2022.
- ALNYLAM PHARMACEUTICALS, INC. interest expense nonoperating for fiscal 2022 was $155.97M.
| Period end | Interest Expense Nonoperating 3 month | Interest Expense Nonoperating 3 month as first filed | Interest Expense Nonoperating 6 month | Interest Expense Nonoperating 6 month as first filed | Interest Expense Nonoperating 9 month | Interest Expense Nonoperating 9 month as first filed | Interest Expense Nonoperating 12 month |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | $82.05M 10-Q · filed 2026-07-30 | $151.34M 10-Q · filed 2026-07-30 | |||||
| 2025-12-31 | $65.40M derived: 10-K 12 month − 10-K 9 month · filed 2026-02-12 | $109.80M derived: sum of 2 quarters · filed 2026-02-12 | $171.25M derived: sum of 3 quarters · filed 2026-07-30 | $252.63M 10-K · filed 2026-02-12 | |||
| 2025-09-30 | $44.40M 10-Q · filed 2025-10-30 | $105.85M derived: sum of 2 quarters · filed 2026-07-30 | $187.23M 10-K · filed 2026-02-12 | $123.29M 10-Q · filed 2025-10-30 | $203.13M derived: sum of 4 quarters · filed 2026-07-30 | ||
| 2025-06-30 | $61.46M 10-Q · filed 2026-07-30 | $40.25M 10-Q · filed 2025-07-31 | $119.77M 10-Q · filed 2026-07-30 | $78.89M 10-Q · filed 2025-07-31 | $158.74M derived: sum of 3 quarters · filed 2026-07-30 | $193.11M derived: sum of 4 quarters · filed 2026-07-30 | |
| 2025-03-31 | $58.31M 10-K · filed 2026-02-12 | $38.65M 10-Q · filed 2025-05-01 | $97.28M derived: sum of 2 quarters · filed 2026-02-12 | $131.66M derived: sum of 3 quarters · filed 2026-02-12 | $164.91M derived: sum of 4 quarters · filed 2026-02-12 | ||
| 2024-12-31 | $38.97M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-12 | $73.35M derived: sum of 2 quarters · filed 2026-02-12 | $106.61M derived: sum of 3 quarters · filed 2026-02-12 | $141.86M 10-K · filed 2026-02-12 | |||
| 2024-09-30 | $34.38M 10-Q · filed 2025-10-30 | $67.63M derived: sum of 2 quarters · filed 2025-10-30 | $102.89M 10-Q · filed 2025-10-30 | $134.22M derived: sum of 4 quarters · filed 2026-02-12 | |||
| 2024-06-30 | $33.26M 10-Q · filed 2025-07-31 | $68.51M 10-Q · filed 2025-07-31 | $99.85M derived: sum of 3 quarters · filed 2026-02-12 | $130.74M derived: sum of 4 quarters · filed 2026-02-12 | |||
| 2024-03-31 | $35.25M 10-Q · filed 2025-05-01 | $66.59M derived: sum of 2 quarters · filed 2026-02-12 | $97.48M derived: sum of 3 quarters · filed 2026-02-12 | $127.52M derived: sum of 4 quarters · filed 2026-02-12 | |||
| 2023-12-31 | $31.34M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-12 | $62.23M derived: sum of 2 quarters · filed 2026-02-12 | $92.27M derived: sum of 3 quarters · filed 2026-02-12 | $121.22M 10-K · filed 2026-02-12 | |||
| 2023-09-30 | $30.89M 10-Q · filed 2024-10-31 | $60.93M derived: sum of 2 quarters · filed 2024-10-31 | $89.88M 10-Q · filed 2024-10-31 | ||||
| 2023-06-30 | $30.04M 10-Q · filed 2024-08-01 | $58.99M 10-Q · filed 2024-08-01 | |||||
| 2022-12-31 | $155.97M 10-K · filed 2025-02-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |